RNA — Atrium Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $235.32m
- $235.32m
- $18.62m
Annual balance sheet for Atrium Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Total Receivables | — | — | 0.1 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 0.856 | 0.483 | 2.85 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 9.44 | 6.7 | 5.51 |
| Total Assets | 10.3 | 7.19 | 8.35 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 33.8 | 26.8 | 41.8 |
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 80.9 | 68.3 | 71.1 |
| Other Equity | |||
| Total Equity | -70.6 | -61.1 | -62.7 |
| Total Liabilities & Shareholders' Equity | 10.3 | 7.19 | 8.35 |
| Total Common Shares Outstanding |